NASDAQ:CDNA - Nasdaq - US14167L1035 - Common Stock - Currency: USD
12.79
-0.05 (-0.39%)
The current stock price of CDNA is 12.79 USD. In the past month the price decreased by -33.7%. In the past year, price decreased by -32.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.53 | 336.11B | ||
AMGN | AMGEN INC | 14.77 | 164.85B | ||
GILD | GILEAD SCIENCES INC | 15.01 | 144.54B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.61B | ||
REGN | REGENERON PHARMACEUTICALS | 12.71 | 60.80B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.87B | ||
ARGX | ARGENX SE - ADR | 102.95 | 36.15B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.54B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.72B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.29B | ||
INSM | INSMED INC | N/A | 19.72B | ||
BIIB | BIOGEN INC | 8.31 | 19.27B |
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.
CAREDX INC
8000 Marina Blvd, 4th Floor
Brisbane California CALIFORNIA 94080 US
CEO: Reginald Seeto
Employees: 647
Phone: 14152872300
The current stock price of CDNA is 12.79 USD. The price decreased by -0.39% in the last trading session.
The exchange symbol of CAREDX INC is CDNA and it is listed on the Nasdaq exchange.
CDNA stock is listed on the Nasdaq exchange.
14 analysts have analysed CDNA and the average price target is 30.16 USD. This implies a price increase of 135.83% is expected in the next year compared to the current price of 12.79. Check the CAREDX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CAREDX INC (CDNA) has a market capitalization of 712.15M USD. This makes CDNA a Small Cap stock.
CAREDX INC (CDNA) currently has 647 employees.
CAREDX INC (CDNA) has a support level at 11.91 and a resistance level at 13.13. Check the full technical report for a detailed analysis of CDNA support and resistance levels.
The Revenue of CAREDX INC (CDNA) is expected to grow by 11.91% in the next year. Check the estimates tab for more information on the CDNA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CDNA does not pay a dividend.
CAREDX INC (CDNA) will report earnings on 2025-08-12, after the market close.
The PE ratio for CAREDX INC (CDNA) is 19.38. This is based on the reported non-GAAP earnings per share of 0.66 and the current share price of 12.79 USD. Check the full fundamental report for a full analysis of the valuation metrics for CDNA.
The outstanding short interest for CAREDX INC (CDNA) is 11.89% of its float. Check the ownership tab for more information on the CDNA short interest.
ChartMill assigns a fundamental rating of 6 / 10 to CDNA. CDNA has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months CDNA reported a non-GAAP Earnings per Share(EPS) of 0.66. The EPS increased by 217.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 16.99% | ||
ROA | 12.02% | ||
ROE | 15.51% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to CDNA. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 13.3% and a revenue growth 11.91% for CDNA